Recombinant human adenovirus type 5 (H101) combined with anti-PD-1 monoclonal antibody in the treatment of patients with advanced melanoma with previous immunotherapy failure: A single-site, ...

Adenovirus Type 5, human recombinant (Oncorine) is a replication selective, recombinant, E1B and partial E3 gene deleted form of human adenovirus type 5, with potential antineoplastic activity. It is ...

Study investigates the link between COVID-19 vaccines and autoimmune/neurological diseases, focusing on Guillain-Barre syndrome (GBS) risks associated with adenovirus vector vaccines.

OXFORD, England & CAMBRIDGE, Mass.--(BUSINESS WIRE)--SpyBiotech, a biotechnology company with a novel vaccine platform technology that can target infectious diseases, cancer, and chronic diseases ...

3. World Health Organization. Interim recommendations for use of the ChAdOx1-S [recombinant] vaccine against COVID-19 (AstraZeneca COVID-19 vaccine AZD1222 Vaxzevria, SII COVISHIELD). Interim ...

Recombinant human adenovirus type 5 (H101) is the first commercialized OVs in the world. The gene encoding the 55 kDa E1B protein responsible for p53 binding and inactivation in H101 has been deleted ...

Such NG pairs are known hotspots for deamidation (Geiger and Clarke, 1987). The recombinant AdC68 constructs studied in the current manuscript had 3 such NG pairs in its hexon primary sequence: N414, ...

In a recent study posted to the bioRxiv* server, researchers assessed the immunogenicity of the self-developed recombinant adenovirus vector (rAd5) vaccine on macaques. They evaluated the efficacy ...

Adenovirus is well beyond the range of conventional mass spectrometry, and it was unclear how well such a large complex could be desolvated. Here, we report molecular weight (MW) distributions ...

According to the statistics of Our World in Data, as of September 2, 2021, Recombinant COVID-19 Vaccine (Adenovirus Vector) jointly developed by AstraZeneca and University of Oxford has been ...

Russia's Sputnik V uses recombinant human adenoviruses Ad26 and Ad5 for the first and second doses, respectively. Finally, China's CanSino vaccine uses the recombinant human adenovirus Ad5.

A multitargeted recombinant adenovirus 5 (Ad5) vaccine platform was shown to be safe and clinically active in a phase 1 trial of patients with metastatic castration-resistance prostate cancer. 1,2 ...